Tue, Sep 13, 2016 - Page 10 News List

Alphabet plans diabetes co-venture


Google parent Alphabet Inc and French drugmaker Sanofi plan to invest about US$500 million in a joint venture to tackle diabetes amid forecasts for the number of people with the disease to surge.

Sanofi is betting the partnership with Alphabet’s Verily Life Sciences LLC will spur advancements in the way diabetes is monitored and treated and help it navigate an increasingly competitive market.

The venture, Onduo, plans to combine devices, software and medicine, according to a statement yesterday from Sanofi and Verily, previously known as Google Life Sciences.

“The beauty of the joint venture in a way is that we don’t rely on the typical 10-year development cycle of a pharmaceutical asset,” Stefan Oelrich, senior vice president and head of the global diabetes franchise at Sanofi, said in an interview. “We start to innovate today.”

Sanofi expects increased competition in the diabetes market to remain as cheaper copies of biotech drugs known as biosimilars are rolled out. It plans to distinguish itself from rivals with programs like the Verily venture, unveiled last year, Oelrich said.

Sanofi is investing US$248 million in cash and Verily is committing an “equivalent” amount, he said.

“With more market entrants and as the space gets more crowded, it will be more difficult to maintain your stance from a contracting and commercial standpoint,” Oelrich said. “There’s increased competition on price. I think it’s here to stay.”

The drugmaker has been reshaping its diabetes portfolio after cutting its three-year sales forecast for the business last year because of a slump in demand for its best-selling medicine, Lantus.

Sanofi is relying on new treatments including its Toujeo insulin to help make up for the Lantus revenue shortfall.

The company plans to step up efforts to convince purchasers that its drugs are better than rivals’ treatments, Oelrich said.

Lantus last month was replaced on CVS Health Corp’s 2017 list of covered drugs by Eli Lilly & Co’s Basaglar, a cheaper version of the insulin that is scheduled to be sold in the US starting in December.

Given Sanofi’s reliance on Lantus, it will be hard for the company to escape near-term pressure as such biosimilars are introduced, according to a Sept. 7 report from Berenberg Bank analysts in London.

Sanofi is carrying out “the biggest real-world evidence” program ever for Toujeo to highlight to payers the differences between the treatments, Oelrich said.

“It’s our job to make sure that we have a convincing value story behind that because not all these products are the same,” he said.

The results of the program, which involve more than 4,500 patients in the US and Europe through three studies, will assess the efficacy of the once-a-day insulin, with results expected next year.

The Sanofi and Verily venture will focus on developing ways to improve medication management and habits for patients and will be led by Joshua Riff as chief executive officer. The company will take advantage of Verily’s experience in miniaturized electronics, analytics and consumer software, according to the statement.

Comments will be moderated. Keep comments relevant to the article. Remarks containing abusive and obscene language, personal attacks of any kind or promotion will be removed and the user banned. Final decision will be at the discretion of the Taipei Times.

TOP top